PURPOSE: This study investigated psychological morbidity, quality of life (QoL), colorectal cancer (CRC)-specific symptoms and supportive care needs in a CRC population at the end of treatment (EOT). METHODS:CRC survivors (n = 152) completed a post-treatment baseline questionnaire as part of a multisite supportive care randomised controlled trial (SurvivorCare). CRC survivors had completed treatment with curative intent within 0 to 6 months. Measures are as follows: Brief Symptom Inventory 18 (BSI-18) (psychological morbidity), EORTC QLQ-C30 and QLQ-CR29 (QoL and CRC-specific symptoms and problems) and Cancer Survivors' Unmet Needs (CaSUN) measure with a simplified response format (unmet needs). Linear regression models were used to compare participants' QoL with a general population sample. Correlation analysis examined associations between psychological morbidity, QoL and CRC-specific symptoms and problems. RESULTS:Average participant age was 64 years, and 51% were male. The majority (68%) had stage 3 disease. In comparison to population norms, CRC survivors had lower depression and anxiety scores (47.4 and 45.6, respectively) but higher somatisation, and lower role, cognitive and social functioning (p < 0.001). CRC survivors had higher fatigue, nausea/vomiting, appetite loss, diarrhoea and financial problems (all p < 0.001), as well as pain (p = 0.002) and constipation (p = 0.019). CRC-specific psychological scores were positively correlated with all three BSI domain scores, and pain and fatigue symptom scores on the QLQ-C30 while negatively correlated with all five functional scales of the QLQ-C30. CONCLUSIONS: CRC survivors reported good mental health at EOT. Role and social functioning were impaired compared to population norms, possibly related to physical symptoms. IMPLICATIONS FOR CANCER SURVIVORS: Findings may help guide consultations with patients and inform the design of more tailored supportive care interventions. TRIAL REGISTRATION: ACTRN12610000207011.
RCT Entities:
PURPOSE: This study investigated psychological morbidity, quality of life (QoL), colorectal cancer (CRC)-specific symptoms and supportive care needs in a CRC population at the end of treatment (EOT). METHODS: CRC survivors (n = 152) completed a post-treatment baseline questionnaire as part of a multisite supportive care randomised controlled trial (SurvivorCare). CRC survivors had completed treatment with curative intent within 0 to 6 months. Measures are as follows: Brief Symptom Inventory 18 (BSI-18) (psychological morbidity), EORTC QLQ-C30 and QLQ-CR29 (QoL and CRC-specific symptoms and problems) and Cancer Survivors' Unmet Needs (CaSUN) measure with a simplified response format (unmet needs). Linear regression models were used to compare participants' QoL with a general population sample. Correlation analysis examined associations between psychological morbidity, QoL and CRC-specific symptoms and problems. RESULTS: Average participant age was 64 years, and 51% were male. The majority (68%) had stage 3 disease. In comparison to population norms, CRC survivors had lower depression and anxiety scores (47.4 and 45.6, respectively) but higher somatisation, and lower role, cognitive and social functioning (p < 0.001). CRC survivors had higher fatigue, nausea/vomiting, appetite loss, diarrhoea and financial problems (all p < 0.001), as well as pain (p = 0.002) and constipation (p = 0.019). CRC-specific psychological scores were positively correlated with all three BSI domain scores, and pain and fatigue symptom scores on the QLQ-C30 while negatively correlated with all five functional scales of the QLQ-C30. CONCLUSIONS: CRC survivors reported good mental health at EOT. Role and social functioning were impaired compared to population norms, possibly related to physical symptoms. IMPLICATIONS FOR CANCER SURVIVORS: Findings may help guide consultations with patients and inform the design of more tailored supportive care interventions. TRIAL REGISTRATION: ACTRN12610000207011.
Authors: J Zabora; K BrintzenhofeSzoc; P Jacobsen; B Curbow; S Piantadosi; C Hooker; A Owens; L Derogatis Journal: Psychosomatics Date: 2001 May-Jun Impact factor: 2.386
Authors: Joseph M Herman; Amol K Narang; Kent A Griffith; Mark M Zalupski; Jennifer B Reese; Susan L Gearhart; Nolifer S Azad; June Chan; Leah Olsen; Jonathan E Efron; Theodore S Lawrence; Edgar Ben-Josef Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-09 Impact factor: 7.038
Authors: Suzanne K Chambers; Xingqiong Meng; Pip Youl; Joanne Aitken; Jeff Dunn; Peter Baade Journal: Qual Life Res Date: 2011-12-27 Impact factor: 4.147
Authors: Anna Boltong; Sanchia Aranda; Russell Keast; Rochelle Wynne; Prudence A Francis; Jacqueline Chirgwin; Karla Gough Journal: PLoS One Date: 2014-07-31 Impact factor: 3.240
Authors: Shaila M Strayhorn; Leslie R Carnahan; Kristine Zimmermann; Theresa A Hastert; Karriem S Watson; Carol Estwing Ferrans; Yamilé Molina Journal: Support Care Cancer Date: 2019-07-24 Impact factor: 3.603
Authors: Jean A McDougall; Cindy K Blair; Charles L Wiggins; Michael B Goodwin; Vi K Chiu; Ashwani Rajput; Anita Y Kinney Journal: J Cancer Surviv Date: 2019-05-20 Impact factor: 4.442
Authors: Michael Jefford; Karla Gough; Allison Drosdowsky; Lahiru Russell; Sanchia Aranda; Phyllis Butow; Jo Phipps-Nelson; Jane Young; Mei Krishnasamy; Anna Ugalde; Dorothy King; Andrew Strickland; Michael Franco; Robert Blum; Catherine Johnson; Vinod Ganju; Jeremy Shapiro; Geoffrey Chong; Julie Charlton; Andrew Haydon; Penelope Schofield Journal: Oncologist Date: 2016-06-15
Authors: Jasmijn F M Holla; Lonneke V van de Poll-Franse; Peter C Huijgens; Floortje Mols; Joost Dekker Journal: Support Care Cancer Date: 2016-02-03 Impact factor: 3.603